Psychedelic Stock Watch explains why astute investors will put their dollars into both "experiential" and non-psychoactive psychedelic drug R&D.
Exploring the companies and themes that make up this emerging and exciting new sector
Mydecine Selects Substance Use Disorder and Smoking Cessation for Novel Psychedelic Molecule MYCO-004
Mydecine's novel molecule, MYCO-004 is targeting multiple forms of addiction/substance abuse.
Numinus Files U.S. Provisional Patent Application for a Proprietary Rapid Production Process for Psilocybe and Other Psychoactive Fungi Species
Numinus files a patent application for a "process" that can allow faster, more cost-effective production of psychoactive compounds such as psilocybin.
Novamind Welcomes Dr. Paul Thielking as Chief Scientific Officer
Novamind's new Chief Scientific Officer is a physician with deep knowledge of psychiatry and palliative care, including familiarity with ketamine-assisted psychotherapy.
Alternatives to ATAI: Go Big Or Go Small?
Sometimes biggest is not "best". Psychedelic Stock Watch offers investors a lot of reasons why thinking SMALLER may be more profitable.
Cybin Announces Completion of its 51st Pre-Clinical Psychedelic Molecule Study
Cybin completes its 51st pre-clinical molecule study, with four of these molecules already being advanced to toward clinical evaluations.
Texas Will Study Benefits Of Psychedelics For Military Veterans Under Bill Enacted Without Governor’s Signature
The governor of Texas allowed a bill that will require the state to study the therapeutic potential of psychedelics to become law without his signature on Friday.
Atai IPO Day An Underwhelming Event
The much-anticipated IPO for atai Life Sciences (US:ATAI) ended up being anti-climactic instead.
Novamind Announces US$1,000,000 Strategic Investment in Stealth Mode Drug Development Company
Novamind has just completed a strategic investment of US$1 million in a private psychedelics company, as part of a $25 million Series A financing.
MINDCURE Develops Proprietary Ketamine-Enhanced Psychotherapy Protocols for Treatment of Pain and Depression
MINDCURE announces two, new ketamine-based treatment protocols: one for pain and one for depression. These new protocols will be distributed via iSTRYM.
Rainbo’s Tonya Papanikolov Believes in the Magic of Mushrooms
Tonya Papanikolov could talk about mushrooms for hours.
Bright Minds Biosciences Announces Application to List on Nasdaq
Bright Minds Biosciences has applied to uplist to the NASDAQ.